Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagnetisMM-6 in transplant-ineligible newly diagnosed multiple myeloma
2024-514139-50-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Elranatamab + daratumumab + lenalidomide with Daratumumab + bortezomib + lenalidomide + dexamethasone (2 arms). Primary endpoints: Dose-limiting toxicities, MRD-negative complete response rate at 12 months and 1 more. Planned start Nov 2022; status: authorised.
02
Drugs
elranatamabdaratumumablenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-514139-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514139-50-00.